AbCellera Biologics Inc. is a pioneer in the field of antibody drug discovery, leveraging a unique engine that sifts through natural immune responses to find promising antibodies for development. With a portfolio of discovery programs at various stages and strategic collaborations with industry giants like Eli Lilly, as well as partnerships focused on GPCR target antibodies, AbCellera stands out in biotech. Founded in 2012 and based in Vancouver, Canada, the company is at the forefront of developing innovative treatments.
Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing. That dislocation between share price and product…
Penny stocks represent an interesting investment opportunity. These stocks typically represent small companies or companies that are early in the development stages. But isn’t that how you make it big in the…
